# Anna Maria Langkilde

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anna-maria-langkilde/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,467 |
| Field | Diabetes Treatment and Management |
| h-index | 75 |
| i10-index | 174 |
| Last Known Institution | AstraZeneca (Brazil) |
| OpenAlex ID | https://openalex.org/A5012551917 |
| ORCID iD | https://orcid.org/0000-0002-1696-9356 |
| Works | 310 |

## Researcher papers

Showing 12 of 18.

- [Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-heart-failure-with-mildly-reduced-or-preserved-ejection/)
- [Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin](https://scholariq.org/papers/effects-of-dapagliflozin-on-body-weight-total-fat-mass-and-regional-adipose/)
- [Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial](https://scholariq.org/papers/effects-of-dapagliflozin-on-development-and-progression-of-kidney-disease-in/)
- [Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus](https://scholariq.org/papers/effect-of-dapagliflozin-on-heart-failure-and-mortality-in-type-2-diabetes/)
- [Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes](https://scholariq.org/papers/effect-of-dapagliflozin-on-worsening-heart-failure-and-cardiovascular-death-in/)
- [Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial](https://scholariq.org/papers/effects-of-dapagliflozin-on-major-adverse-kidney-and-cardiovascular-events-in/)
- [Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus](https://scholariq.org/papers/effect-of-dapagliflozin-on-atrial-fibrillation-in-patients-with-type-2-diabetes/)
- [A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy](https://scholariq.org/papers/a-pre-specified-analysis-of-the-dapa-ckd-trial-demonstrates-the-effects-of/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled/)
- [Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled-2/)
- [Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled-3/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)

## Researcher university

- [AstraZeneca (Brazil)](https://scholariq.org/institutions/astrazeneca-brazil/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.